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Abstract
Glutamate signaling plays a major role in addiction. Preclinical research strongly suggests an implication of G-protein-
coupled metabotropic glutamate receptor subtype 5 (mGluR5) in nicotine addiction and alcohol use disorder. In
humans, smoking is related to a global reduction in mGluR5 availability. In the present study, we investigated mGluR5
in vivo in patients with alcohol use disorder without the confounding effects of smoking. A total of 14 male subjects
with alcohol use disorder and at least a 25-day abstinence and 14 matched male non-smoking healthy controls were
included in the study. We employed positron emission tomography (PET) with the mGluR5-speciﬁc radiotracer [11C]
ABP688, using a bolus/infusion protocol. We found increased mGluR5 DVR in several regions within the temporal lobe
in patients, as compared to controls. The largest between-group difference was in the amygdala. There was a marked
positive relation between mGluR5 DVR in the anterior cingulate and mGluR5 DVR in the orbitofrontal cortex in
patients, but not in controls. In patients, lower temptation to drink was related to higher amygdala mGluR5 DVR. We
did not ﬁnd altered mGluR5 DVR in the basal ganglia of subjects recovering from alcohol use disorder. In conclusion,
our study provides clinical evidence for altered mGluR5 signaling in the amygdala in alcohol use disorder. This
alteration was associated with the temptation to drink. In addition, this study suggests abnormal mGluR5 signaling in a
network underlying reward-related behavioral ﬂexibility. These ﬁndings strengthen the case for pharmacological
agents acting on mGluR5 as promising candidates for the treatment of alcohol use disorder.
Introduction
Alcoholism is an important risk factor for many disease
conditions, including neuropsychiatric disorders, and a
major contributor to years of life lost to disability and
premature death.1 Alcohol use disorder is characterized
by intense craving and compulsive intake of alcohol
despite its adverse consequences.2 Glutamate signaling in
the brain plays a major role in the pathogenesis of
addiction disorders.3–5 Glutamate acts on ionotropic
receptors and G-protein-coupled metabotropic receptors,
of which, currently, eight subtypes with distinct molecular
and pharmacological properties have been described
(metabotropic glutamate receptor subtypes 1–8
(mGluR1–8), correspondingly).6 Preclinical studies
implicate mGluR5 in binge alcohol intake.7–9 Prolonged
alcohol intake can increase mGluR5 protein levels in the
nucleus accumbens and the amygdala, depending on the
experimental protocol.10–13 Reversely, systemic adminis-
tration of mGluR5 negative allosteric modulators (NAMs)
can inhibit alcohol self-administration.7 More speciﬁcally,
intracranial injections of mGluR5 NAMs directly into the
nucleus accumbens and the amygdala reduce alcohol
intake and reinstatement of alcohol seeking.11–16
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Altogether, these preclinical studies provide a strong
rationale for investigating mGluR5 in the amygdala and
the nucleus accumbens in patients with alcohol use
disorder.
A recent study employing positron emission tomo-
graphy (PET) with the mGluR5 tracer 18F-3-ﬂuoro-5-
[(pyridin-3-yl)ethynyl] benzonitrile (18F-FPEB) addressed
this issue.17 However, 11 out of the 16 patients in that
study were smokers, whereas all controls were non-
smokers. Our work has demonstrated a global reduction
in mGluR5 in current smokers and ex-smokers.18,19
Therefore, a study focusing on non-smoking participants
is needed to exclude the confounding effects of smoking
on mGluR5. To this end, we investigated mGluR5 in non-
smoking male patients recovering from alcohol use dis-
order and healthy non-smoking male controls, employing
PET with the mGluR5-speciﬁc radiotracer 3-(6-methyl-
pyridin-2-ylethynyl)-cyclohex-2-enone-O-11C-methyl-
oxime ([11C]ABP688).20,21 We compared mGluR5 binding
between patients and controls throughout the brain, with
a focus on the nucleus accumbens and the amygdala.
Since alcohol use disorder displays aberrant resting-state
connectivity in functional magnetic resonance imaging
(fMRI) studies,22,23 we also investigated how correlations
of mGluR5 binding among different brain regions differ in
patients vs. controls.
Materials and methods
Participants
Study participants comprised non-smoking individuals
who met the diagnostic criteria for moderate (n= 3) or
severe (n= 11) alcohol use disorder with at least 25 (SD±
18.1) days of continuous abstinence from admission to the
hospital to the day of the scan, according to DSM-5
(Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition; American Psychiatric Association, 2013),
and healthy controls (n= 14). Only male patients were
included in the study because we did not ﬁnd female
patients who fulﬁlled the inclusion criteria. We did not
exclude research subjects from the analysis. Table 1 shows
the demographic and clinical characteristics of the two
samples. Patients were recruited through the Forel Hos-
pital, Alcohol Relapse Prevention Unit, Ellikon an der
Thur, Switzerland, and were all inpatients during study
participation. Controls were recruited through online
advertisements. We chose the sample size based on our
previous PET studies with this tracer.18,19,24,25
Participants were included into the study only after full
explanation of the goals and procedures of the study and
the risks of the study procedures. Informed consent was
obtained from all subjects. The study and the written
consent were approved by the local ethics committee
(Kantonale Ethikkommission Zürich).
Table 1 Demographic and clinical characteristics of the study samples
Patients Healthy controls
Age 46.6 (13.6) 44.1 (12.4)
Gender (male/female) 14/0 14/0
Onset alcohol use disorder
Age >18 years n = 7 —
Age >40 years n = 7 —
Duration of alcohol use disorder, in years 9.4 (7.8) —
BDI 3.5 (3.2) 1.1 (1.7)a
BAI 2.1 (1.9) 0.9 (1.9)
AUDITb 25 (7.5) —
Number of drinks per week prior to
admission
77 (49) 4.2 (2.5), information from 6 participants
only
Tobacco/cannabis consumption — —
Medication n = 10, of these: 7 antidepressants (1 plus Ritalin), 1 Campral, 1
Lyrica, 1 Lyrica and Keppra
—
Highest education High school: n = 9; college: n = 4; academic: n = 1 High school: n = 2; college: n = 8;
academic: n = 4
Psychiatric history MDD n = 8; one also has ADHD —
Numeric values represent the mean (SD), unless indicated otherwise. N refers to the number of participants within this category
aP-value < 0.05, two-sided, comparing patients and controls with Welch′s test for independent samples
bAUDIT=Alcohol use disorders identiﬁcation test (a score of ≥8 indicates harmful or hazardous drinking; score ≥15 in men indicates alcohol use disorder)
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A psychiatrist and a psychologist carried out all inter-
views and clinical assessments. Psychiatric diagnoses were
established via an unstructured clinical interview by the
psychiatrist and a structured interview using the Struc-
tured Clinical Interview for the DSM.2 Exclusion criteria
for patients comprised current medical or neurological
disorder, abnormal blood coagulation, cigarette smoking,
nuclear medicine examination in the last 5 years, major
comorbid psychiatric conditions such as schizophrenia,
bipolar disorder, current depressive episode and addiction
disorders other than alcohol use disorder. Smoking and
psychiatric and medical conditions were exclusion criteria
for controls.
Additional clinical measures included the Beck Anxiety
Inventory (BAI),26 the Beck Depression Inventory (BDI),27
the Alcohol Use Disorders Identiﬁcation Test (AUDIT)28
and the Alcohol Abstinence Self-Efﬁcacy Scale (AASE).29
Based on the AASE, craving for the rewarding effects of
alcohol was calculated as the sum of items 4, 8, 15, 17 and
20 (reward craving), whereas craving for the stress
relieving effects of alcohol was measured with the sum of
items 3, 6, 12, 16 and 18 (relief craving), as previously
suggested.30
In order to assess the relationship between anti-
depressant medication, mGluR5 distribution volume ratio
(DVR) and relapse, we calculated imipramine dose
equivalents for all antidepressants. These calculations
were based on dose conversion factors proposed
elsewhere.31
Positron emission tomography
We used a bolus/infusion protocol evaluated in our
previous work.18,32 A total of 570–624MBq of [11C]
ABP688 in a 50ml volume was administered using an
infusion pump (half was given as a bolus over 2 min and
the other half was infused over the next 58min). Image
acquisition and reconstruction were performed as pre-
viously described.18 All scans started between 1530 and
1600 h local time. Visual inspection of the tissue time
activity curves did not reveal differences between diag-
nostic groups with respect to tracer kinetics.
Statistical analysis
We based our analyses on a maximum probability atlas
implemented in the PMOD PNEURO-Tool (Version 3.6;
PMOD Technologies, Switzerland, www.pmod.com). For
participants, no MRIs were available. Therefore, the
maximum probability atlas and automatic region of
interest segmentation was based on the early frames of the
PET which were normalized to the template. The
template-based segmented regions were then auto-
matically back projected on the original individual PET
image. The regions of interest were visually controlled by
a trained reader and slight corrections were applied if
needed to ensure correct placement (especially in the
basal ganglia area). The DVR for each region of interest
was calculated based on the late imaging frames showing
equilibrium (45–60min) and the cerebellum as a refer-
ence region as previously reported for the bolus-infusion
paradigm.32–34 Two-tailed Welch's tests, which do not
assume equal variance in the compared samples, and
General Linear Model repeated measures analyses were
used to test the differences in mGluR5 DVR and clinical
values between and within the groups. We did not esti-
mate variance and did not test variance equality. We did
not perform partial volume corrections as no MRI was
available to assess and correct for alcohol use disorder-
related atrophy. The standard maps were manually
adapted for regions such as the amygdala and caudate in
case the outline was not acceptable based on the early-
phase image (perfusion like maps). Therefore, a correction
for individual local size differences was performed to
reduce potential effects of reduced gray matter thickness.
We assessed correlations between mGluR5 DVR among
brain regions and inter-regional correlation differences
between patients and controls in a three-step procedure.
First, we calculated a correlation matrix comprising 36
brain regions within each group using Pearson's correla-
tion coefﬁcient. This resulted in 630 correlations per
group reﬂecting the relation between mGluR5 DVR in
630 unique pairs of brain regions. In a second step, we
compared both groups by applying an r-to-z transforma-
tion to all 630 unique correlations in each group and
calculating Welch's test (package “psych” version 1.7.5 in
R version 3.3.2, R Foundation for Statistical Computing,
Vienna, Austria, available at https://cran.r-project.org/).
Following this global between-group comparison, in a
ﬁnal step, we compared each one of the 630 unique cor-
relations between controls and patients. We carried out
these individual comparisons with Fisher′s r-to-z trans-
formation, as implemented in the package “cocor” (ver-
sion 1.1–3) in R. We set a signiﬁcance threshold of p<
0.001 (one-tailed, uncorrected for multiple testing). For
illustration purposes, we displayed the correlation matri-
ces in both groups separately and the numerical correla-
tion differences between patients and controls as color
maps (Figures S1-S2 and Fig. 2a, respectively).
We assumed that the data are normally distributed.
Explorative analyses of mGluR5 DVR values with
Shapiro–Wilk tests yielded signiﬁcant deviations from
normality in healthy controls in the straight gyrus, the
posterior part of the superior temporal gyrus, the infer-
iolateral remainder of the parietal lobe, pallidum, insula
and the anterior cingulate gyrus (p< 0.05, uncorrected for
multiple comparisons). We also found signiﬁcant devia-
tions from normality in subjects with alcohol use disorder
in the superior parietal gyrus and the cuneus (p< 0.05,
uncorrected for multiple comparisons). Based on these
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results, we decided to display individual data points in
scatterplots for between-group comparisons of mGluR5
DVR values and for between-group comparisons of cor-
relations (Figs. 1 and 2) to demonstrate that our ﬁndings
are not a statistical artifact caused by outliers.
Results
Table 1 presents a summary of the demographic and
clinical characteristics of all study participants. The gen-
der of all participants was male. Age did not differ sig-
niﬁcantly between groups (t(25.79)= 0.49, p= 0.63).
Patients reported signiﬁcantly higher BDI scores (t(19.99)
= 2.5, p= 0.02) and BAI scores that were higher but did
not reach criteria for statistical signiﬁcance (t(26)= 1.7, p
= 0.1).
To compare mGluR5 DVR between both groups, we
carried out a multivariate analysis of covariance with
mGluR5 DVR in 36 brain regions as dependent variables,
group as a ﬁxed factor and BDI and BAI as covariates.
Whereas no multivariate difference between both groups
was found (p> 0.05), post hoc analysis of variance
(ANOVA) for all regions indicated that mGluR5 DVR was
signiﬁcantly increased in various brain regions in patients,
mainly in the temporal lobe (Table 2). The most
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Fig. 1 a Amygdala mGluR5 DVR in patients (red) and controls (blue). b The relation between mGluR5 DVR in the amygdala and the total craving score
of the AASE in the patient group.30 c Amygdala mGluR5 DVR in patients who reported a relapse after 3–6 months and those who reported they
remained abstinent. d The mean imipramine equivalent dose of antidepressants at the timepoint of scanning in patients who reported a relapse, as
compared to those who remained abstinent
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prominent effect was in the amygdala (F(1, 26)= 11.76, p=
0.005; Fig. 1a).
Next, we investigated the relation between amygdala
mGluR5 DVR and clinical variables. We found negative
correlations between amygdala mGluR5 binding and the
AASE scores for reward craving and relief craving (rho=
−0.79, p= 0.001; rho=−0.8, p= 0.001, respectively, Fig.
1b). Age, alcohol consumption per week (glasses), dura-
tion of alcohol use disorder (years), age of onset and
abstinence duration prior to scan did not correlate
with mGluR5 DVR in the amygdala (all p> 0.07). For the
other brain regions we found no signiﬁcant correlations
with any of these variables except for a negative correla-
tion between mGluR5 DVR in the superior frontal gyrus
(r=−0.593, p< 0.05) and superior parietal gyrus (r=
−0.622, p< 0.05) with age. Furthermore, we found no
signiﬁcant difference in mGluR5 DVR between patients
with and without family history of alcohol use disorder in
any brain region or any of the clinical parameters
mentioned above. Amygdala mGluR5 DVR was higher in
medication-free persons (n= 4) with alcohol use disorder
than those taking antidepressants (n= 7, t(7.813)= 3.539,
p< 0.01).
Patients with MDD in their history did not show dif-
ferent mGluR5 DVR in the amygdala or any other region
compared to those without MDD in the past. Importantly,
no patient fulﬁlled the diagnostic criteria for current
MDD. Thus, the use of antidepressants was not related to
an acute depressive disorder, but provided to prevent
further depressive episodes in remitted patients or to
reduce depressive symptoms during withdrawal from
alcohol. In the seven cases treated with antidepressants,
the mean imipramine equivalent dose was 139.4± 97.8
(average± standard deviation). Within the patient sample
(n= 14), imipramine equivalent correlated negatively
with mGluR5 DVR in the subgenual anterior cingulate
region (r=−0.56, p< 0.05; uncorrected for multiple
comparisons).
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After 3 to 6 months we contacted the patients by tele-
phone to ask whether they relapsed. Out of 14 partici-
pants, 8 reported that they relapsed during this time
window. We found no signiﬁcant relation between relapse
and amygdala mGluR5 DVR (Fig. 1c) or any other ima-
ging or clinical parameter, except the use of anti-
depressants. Antidepressant medication at the time of
scanning, as estimated by imipramine equivalents, was
higher in patients who relapsed. However, this difference
did not reach statistical signiﬁcance (t8.28= 2.02; p= 0.08,
two-tailed; Fig. 1d).
The inter-regional correlation analysis showed a global
pattern of positive correlations between mGluR5 DVR in
various brain regions across the entire brain in both
groups (Figures S1 and S2). Overall, correlations were
higher in patients than in controls, as indicated by
Welch's two-sample t-test of z-transformed correlation
values (t1189.8= 2.21, p= 0.03, two-tailed, Figure S3).
Welch's two-sample t-test with the non-transformed
correlation values yielded a similar result (t1101.7= 3.53,
p< 0.01, two-tailed). At a descriptive level, the graphical
representation of the correlation differences between
groups suggested that mGluR5 DVR in the anterior cin-
gulate cortex (ACC) and the insula were more strongly
related to mGluR5 DVR in other brain regions in patients
than in controls (Fig. 2a). This difference was particularly
strong for the correlations between mGluR5 DVR in the
ACC and three anatomically contiguous structures, the
straight gyrus, the middle and the posterior orbitofrontal
cortex (OFC). Whereas in patients higher mGluR5 in the
ACC closely corresponded to higher mGluR5 in the
middle, the posterior OFC and the straight gyrus, we did
not ﬁnd such relations in controls (p< 0.001, one-tailed,
uncorrected for multiple comparisons; Table S1, Fig. 2b).
A simulation analysis with randomly generated values
corroborated the validity of these results (see Supple-
mentary Information, Figures S4 and S5).
Discussion
The present study investigated mGluR5 DVR in male
non-smoking patients with alcohol use disorder after
abstinence for at least 25 days compared to healthy age-
matched non-smoking male controls. We found increased
mGluR5 DVR in various brain regions located in the
temporal lobe in alcohol use disorder. This effect was
particularly strong in the amygdala. In patients, but not in
controls, higher mGluR5 DVR in the ACC corresponded
to higher mGluR5 DVR in the medial, posterior OFC and
the straight gyrus. In patients, lower temptation to drink,
as reported in the AASE questionnaire, was related to
higher amygdala mGluR5 DVR.
Preclinical research implicates mGluR5 signaling in
alcohol use disorder.7–9 Ethanol exposure can increase
mGluR5 levels in the nucleus accumbens.10,11,13, A com-
plex pattern of ﬁndings suggests that intermittent alcohol
exposure can transiently increase mGluR5 levels in the
central nucleus of the amygdala.10,12, Reversely, systemic
administration of mGluR5 NAMs, at doses that occupy
50–80% of mGluR5, can suppress self-administration of
ethanol without impairing self-administration of food.7
Direct intracranial injections of mGluR5 NAMs into the
amygdala and nucleus accumbens reduce alcohol intake
and the reinstatement of alcohol seeking in rodents.11–16
Clinical studies on mGluR5 in alcohol use disorder are
scarce. A post-mortem investigation of brain samples
found no alcoholism-associated alterations in mGluR1/5
Table 2 Comparison of mGluR5 DVR in subjects with alcohol use disorder and healthy controls
Brain regiona Patients mean (SD) Controls mean (SD) F(1, 26) p-value Partial ε
2
Hippocampus 1.76 (0.18) 1.65 (0.12) 3.8 0.062 0.127
Amygdala 1.91 (0.20) 1.69 (0.14) 11.76 0.005 0.311
Anterior temporal lobe, medial part 1.94 (0.16) 1.80 (0.13) 6.24 0.019 0.194
Anterior temporal lobe, lateral part 2.00 (0.16) 1.84 (0.13) 9.38 0.005 0.265
Parahippocampal and ambient gyri 1.85 (0.20) 1.65 (0.13) 9.06 0.006 0.258
Superior temporal gyrus, posterior part 1.79 (0.13) 1.70 (0.12) 3.89 0.059 0.130
Middle and inferior temporal gyrus 1.92 (0.16) 1.78 (0.13) 6.13 0.020 0.191
Gyrus fusiformes 2.01 (0.19) 1.87 (0.12) 4.95 0.035 0.160
Posterior temporal lobe 1.79 (0.14) 1.68 (0.09) 6.06 0.021 0.189
Superior temporal gyrus, anterior part 1.83 (0.15) 1.70 (0.13) 5.56 0.026 0.176
aBrain regions as implemented in PMOD (http://doc.pmod.com/pneuro/7674.htm); mean (SD) refers to the average and the standard deviation of the mGluR5 DVR in
the corresponding brain region in patients and controls; F-values for the effect of group in post hoc ANOVAs; p-values for the effect of group; partial ε2, as calculated in
SPSS, indicates the effect size
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density in the nucleus accumbens, putamen and cau-
date.35 An in vivo PET study using the mGluR5-selective
radioligand 18F-FPEB reported reduced tracer binding in
subjects with alcohol use disorder.17 Of note, approxi-
mately 69% of individuals with alcohol use disorder and
none of the controls in that study were smokers.17 This is
especially relevant, as we previously showed marked glo-
bal reduction in mGLuR5 binding in smokers.18,19, These
global effects were particularly strong in brain regions that
overlap with the anatomical distribution of the effects
reported by Leurquin-Sterk et al.17
Based on our previous investigations on mGluR5 in
humans, we carefully controlled for clinical variables that
might confound our ﬁndings in the present investigation.
Since we showed reduced mGluR5 DVR in depression in a
previous study,33 we excluded patients with current major
depressive episodes and other mood disorders from our
present investigation. Moreover, given that smoking is
associated with a global reduction in mGluR5, we also
excluded smokers.18,19, As rodent data suggest that anti-
depressants might increase mGluR5 levels,36,37, we tested
for a possible confounding effect in the present study.
Amygdala mGluR5 DVR was lower in patients treated
with antidepressants than in patients who did not receive
antidepressants. Thus, our ﬁnding of higher amygdala
mGluR5 DVR in patients, as compared to controls, cannot
be explained by antidepressant medication.
Studies in rodents show that mGluR5 signaling is
involved into the reinstatement of alcohol and nicotine
self-administration.7,8, In humans, we found that in ex-
smokers mGluR5 DVR was related to the risk for
relapse.19 Based on these results, we investigated whether
mGluR5 DVR relates to the risk for relapse in alcohol use
disorder. We did not ﬁnd evidence that mGluR5 DVR was
predictive of relapse in patients with alcohol use disorder.
We observed higher positive relation between mGluR5
DVR in the ACC and OFC in patients. This ﬁnding is
particularly interesting in view of the fact that resting-
state connectivity between the ACC and OFC, as mea-
sured with fMRI, is higher in alcoholics than in healthy
controls.23 These converging results, from PET and fMRI,
appear plausible from neuroanatomical point of view
since both structures are structurally and functionally
connected.38,39, Moreover, these regions are critical for
reward-related behavioral control and ﬂexibility, both of
which are impaired in addiction.40–43
In conclusion, our study provides clinical evidence for
the implication of mGluR5 in the amygdala, OFC and
ACC in alcohol use disorder.3,4, Our ﬁndings strengthen
the case for mGluR5-targeted pharmacological treatment
of alcohol use disorder.5,7–9,44 mGluR5 NAMs have shown
promising results in preclinical addiction models.7 Partial
mGluR5 NAMs also show promising results and are
currently in development.45,46, The present study suggests
that these pharmacological agents may be helpful in the
treatment of alcohol use disorder.5
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